Your esophagus is the tube that carries food from your mouth to your stomach. Gastroesophageal reflux disease (GERD) happens when a muscle at the end of your esophagus does not close properly. This allows stomach contents to leak back, or reflux, into the esophagus and irritate it.

You may feel a burning in the chest or throat called heartburn. Sometimes, you can taste stomach fluid in the back of the mouth. If you have these symptoms more than twice a week, you may have GERD. You can also have GERD without having heartburn. Your symptoms could include a dry cough, asthma symptoms, or trouble swallowing.

Anyone, including infants and children, can have GERD. If not treated, it can lead to more serious health problems. In some cases, you might need medicines or surgery. However, many people can improve their symptoms by

  • Avoiding alcohol and spicy, fatty or acidic foods that trigger heartburn
  • Eating smaller meals
  • Not eating close to bedtime
  • Losing weight if needed
  • Wearing loose-fitting clothes

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for GASTROOESOPHAGEAL REFLUX DISEASE


Potassium clinical trials, surveys and public health registries

Find Drug Side Effect reports

Potassium Side Effects

Hyperkalaemia (64)
Nausea (46)
Pain (45)
Dyspnoea (43)
Dizziness (42)
Asthenia (41)
Fatigue (37)
Cardiac Arrest (34)
Diarrhoea (33)
Completed Suicide (29)
Vomiting (28)
Renal Failure (28)
Oedema Peripheral (27)
Chest Pain (26)
Anxiety (26)
Pain In Extremity (25)
Muscle Spasms (25)
Fall (24)
Death (24)
Pyrexia (23)
Headache (22)
Weight Decreased (22)
Hypersensitivity (21)
Blood Potassium Increased (21)
Renal Failure Acute (20)
Arthralgia (20)
Injury (19)
Abdominal Pain (19)
Cough (19)
Hypotension (19)
Pneumonia (18)
Dehydration (18)
Abdominal Pain Upper (18)
Back Pain (18)
Confusional State (17)
Anaemia (17)
Depression (17)
Hypertension (17)
Overdose (17)
Malaise (17)
Cerebrovascular Accident (16)
Hypokalaemia (16)
Rash (15)
Respiratory Failure (15)
Injection Site Pain (15)
Cardiac Failure Congestive (15)
Blood Potassium Decreased (14)
Feeling Abnormal (14)
Product Quality Issue (14)
Thrombocytopenia (14)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Recent Reviews


High potassium what are the side effects

I have takesn ecoclav dua for thorate infection what is harm

I want to know whether losartan casuse erectile disfunction ( E D )

A flu epidemic at a boarding school would be a concern for the Centers for Disease Control true or false?

Why do doctors keep the availabilty of the test for DPD deficiency a secret??? My sister is a doctor, infectious disease, at St Francis in Charleston, SC. Our father was treated by an oncologist well known to my sister, a 'colleague' you might s

I am having cramps, muscle pain, memory loss, I have been on Revlmid for about 1 year. Does anybody else my age have this disease, I am only 46 yr woman.

<b><span style=' padding: 0px; margin: 0px;'>Hi Can any1 tell me why this medicine (Betaserc) people use and if the disease is dangerous....plz tell me on urgent basis...any1 thnx</b>

I was given Clindamycin (150 MG Capsule) to take for 10 days 4 times daily for tooth extractions aftercare. It gives me splitting headaches and acid reflux . Evdokia

Bad taste in my mouth, very bloated and abdominal pain and reflux

<strong>I have very high blood pressure, was put on this drug approximately 5 weeks ago. I was on Coozar previous to this. I also take paracetamol x 1 bd, ceres x 1, venlafaxine x 1, omeprazole x 1, aspirin x 1, have Charcot Marie Tooth Disease

55 yo dx with osearthritis and degenative disc disease, prescribed Mobic 15 mg once a day on medication for past year with no problem.For the past 6weeks had gradual onset of facial and extremity edema , esophageal spasm and expir

:( alas, tried it for one month and not good!. main problems, bloating, abdominal discomfort, reflux/heartburn,[had to try sleep sitting up], symptoms went on stopping, returned on restart, did lower my BP but too high a cost!.

About half an hour after taking Crestor I get a bad dose of reflux...which I have under control with medication.....but oh boy is it giving me a hard time. Dull aches around knee joints wake me during the night. Sinus is bad again too!


Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Bioavailability of Potassium From Potatoes and Potassium Gluconate
Conditions: Potassium Bioavailability;   Blood Pressure
Interventions: Dietary Supplement: Placebo control;   Dietary Supplement: Low dose Potassium gluconate;   Dietary Supplement: Medium dose Potassium gluconate;   Dietary Supplement: High dose Potassium gluconate;   Dietary Supplement: Low dose potato;   Dietary Supplement: Medium dose potato;   Dietary Supplement: High dose potato;   Dietary Supplement: High dose French fries;   Dietary Supplement: Basal diet control
Outcome Measures: Bioavailability of Potassium;   Blood Pressure Response to Potassium
2 Not yet recruiting Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions
Condition: Hyperkalemia
Intervention: Behavioral: decision support in Potassium-inc. drug-drug-interactions
Outcome Measures: Impact on serum Potassium monitoring during Potassium-increasing drug-drug-interactions;   Frequency of hyperkalemia during Potassium-increasing drug-drug-interactions;   Frequency of Potassium-increasing drug-drug-interactions ordered in the presence of hyperkalemia;   Frequency of transfers to the ICU during Potassium-increasing drug-drug-interactions in function of the serum Potassium level;   Frequency of death during Potassium-increasing drug-drug-interactions in the presence or absence of hyperkalemia;   Change in frequency distribution of serum Potassium monitoring intervals;   Response of physicians to the computer-based alerts and reminders
3 Recruiting Comparison of Enteral Versus Intravenous Potassium Supplementation
Condition: Acute Hypokalemia
Interventions: Drug: Intravenous Potassium chloride;   Drug: Oral Potassium chloride
Outcome Measures: The efficacy EPR and IVPR for treatment of hypokalemia (measured as change in serum Potassium levels in milliequivalent/liter (mEq/L) after Potassium replacement;   Comparison of adverse effects after EPR and IVPR.;   Comparison of number of dose/s required to achieve resolution of hypokalemia;   Efficacy of EPR and IVPR for various degrees of severity of hypokalemia for each episode of hypokalemia
4 Unknown  Effect of Rapid Transfusion With Fluid Management System (FMS) on Plasma Potassium in Liver Transplantation Recipients
Condition: Condition Requiring Rapid Transfusion During Liver Transplantation Surgery
Outcome Measures: Potassium concentration in the Fluid Management System (FMS) reservoir;   plasma Potassium of the patient
5 Not yet recruiting Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature
Condition: Nephrocalcinosis
Interventions: Drug: Potassium Citrate;   Drug: Placebo
Outcome Measures: incidence of nephrocalcinosis in extremely preterm infants;   Determine whether the administration of Potassium citrate in extreme premature decreases neonates the levels of calcium and calcium / creatinine ratio in urine in each of the branches of treatment at 38-40 weeks;   To determine whether administration of Potassium citrate improves the levels of urinary phosphorus, Potassium, sodium, citrate, creatinine, oxalate, ratio citrate / calcium , and ph value;   Determine whether the administration of Potassium citrate improves the plasma levels of sodium, Potassium, creatinine, calcium, and ph value.;   To determine the incidence of adverse events and serious adverse events related to study treatment.
6 Unknown  Effects of Potassium Salts on Blood Pressure and Target Organ Damage
Condition: Hypertension
Intervention: Behavioral: Potassium supplementation
Outcome Measures: Blood pressure and markers of target organ damage and bone health at 4 weeks of Potassium supplementation.;   Comparisons among different treatments in blood pressure and markers of target organ damage and bone health.
7 Recruiting Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension
Condition: Hypertension
Interventions: Drug: Potassium chloride powder;   Drug: Potassium citrate powder;   Drug: Potassium magnesium citrate powder;   Drug: Placebo
Outcome Measures: 24-hour blood pressure;   Office blood pressure;   Serum C-terminal telopeptide (CTX);   24-hour urinary calcium;   Carotid to femoral pulse wave velocity;   Central aortic blood pressure
8 Recruiting Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter
Conditions: Atrial Fibrillation;   Atrial Flutter;   Potassium;   Cardioversion
Intervention: Drug: Potassium chloride
Outcome Measures: Cardioversion (time and percentage);   Atrial fibrillation at 3 months follow up visit and during 72 hours ECG-monitoring period.
9 Recruiting Combined Dietary Education of Low Sodium and High Potassium Consumption
Conditions: Prehypertension;   Hypertension
Interventions: Behavioral: dietary education of low sodium and high Potassium consumption;   Behavioral: dietary education of low sodium consumption only
Outcome Measures: changes of 24-hour ambulatory systolic and diastolic blood pressure;   changes of 24-hour urine sodium and Potassium excretion;   changes of renin and aldosterone
10 Not yet recruiting Investigating a New Way of Giving Medicine to Newborn and Preterm Babies
Conditions: Hypophosphataemia;   Osteopenia of Prematurity
Interventions: Drug: Oral thin film therapy (Potassium acid phosphate oral thin films);   Drug: Standard therapy (Potassium acid phosphate oral solution)
Outcome Measures: Serum phosphate;   Age-appropriateness
11 Unknown  Glucose Insulin Potassium With Intensive Insulin Therapy and (GIK2) Versus GIK Alone
Condition: Acute Coronary Syndrome
Interventions: Drug: glucose insulin Potassium;   Drug: GIK and intensive insulin therapy
Outcome Measures: 30 days mortality, reinfarction, urgent coronary revascularisation, and stroke.;   Severe dysrhythmias, acute left ventricular failure with ejection fraction<45%, change of serum B-type natriuretic peptide (BNP), serum troponin, and platelet factor activator (PFA-100) within 24 hours after the start of protocol treatment.
12 Recruiting Potassium Citrate Supplementation vs. Dietary Counseling
Condition: Kidney Stone
Interventions: Dietary Supplement: Potassium Citrate Supplementation;   Other: Dietary Education
Outcome Measure: Change in 24-hour urine parameters
13 Recruiting Musculoskeletal Effects of Bicarbonate
Conditions: Age-related Bone Loss;   Age Related Muscle Loss;   Falls;   Fractures
Interventions: Dietary Supplement: Potassium bicarbonate;   Other: placebo
Outcome Measures: The primary aim is to identify the dose of KHCO3 needed for maximal suppression of 24-hr urinary N-telopeptide/creatinine ratio;   The secondary aim is to identify the dose of KHCO3 needed for maximal suppression of 24-hr urinary nitrogen/creatinine ratio
14 Recruiting Perioperative Chemotherapy for Potentially Resectable Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: Tegafur, Gimeracil and Oteracil Potassium Capsules;Oxaliplatin;   Drug: Oxaliplatin; Capecitabine
Outcome Measures: Disease-free survival(DFS);   Objective response rate (ORR);   Disease control rate (DCR);   Down staging rate;   Overall survival (OS);   Adverse events;   R0-resection rate
15 Unknown  Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum
Condition: Molluscum Contagiosum
Interventions: Drug: Hydroxide Potassium;   Drug: Placebo
Outcome Measure: Efficacy (diseappearance of lesions)
16 Unknown  The Effects of Potassium Citrate on Bone Metabolism
Conditions: Bone Diseases, Metabolic;   Osteoporosis, Postmenopausal
Intervention: Drug: Potassium citrate
Outcome Measures: Bone turnover markers;   Bone Density by DEXA
17 Recruiting Effectiveness of Two Water-Based Potassium Oxalate Desensitizers on Dental Hypersensitivity
Condition: Dentin Sensitivity
Intervention: Device: Potassium oxalate
Outcome Measure: Dentin sensitivity
18 Recruiting Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis
Conditions: Glomerulonephritis;   Proteinuria
Interventions: Drug: Shenyankangfu tablets;   Drug: Losartan Potassium 50mg;   Drug: Shenyankangfu tablets and Losartan Potassium 50mg;   Drug: Shenyankangfu tablets and Losartan Potassium 100mg;   Drug: Losartan Potassium 100mg
Outcome Measures: changes of 24 hours proteinuria after the treatment;   changes of serum creatinine after treatment;   changes of eGFR after the treatment;   changes of Traditional Chinese Medicine syndrome scores after the treatment
19 Recruiting Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment
Condition: Cough
Interventions: Drug: Syrup of oxomemazine, guaifenesin and Potassium iodate;   Drug: Syrup of guaifenesin
Outcome Measures: Reduction/improvement of cough symptoms;   Tolerance
20 Unknown  Relationship Between Potassium Level in Venous Blood Samples Drawn and Heel Sticks In Infants and Newborns
Condition: Healthy Infants
Outcome Measure: Potassium Measurements